BACKGROUND/OBJECTIVES: It is unknown what causes uraemic symptoms in renal disease. Chronic kidney disease (CKD) patients are known to have increased levels of urea, sodium, potassium and phosphate in their saliva compared with those without renal disease. The present cross-sectional study investigated associations between known genetic traits of taste and self-reported upper gastrointestinal (GI) symptoms experienced in CKD patients with the changes in saliva composition found in renal failure. SUBJECTS/METHODS: Fifty-six CKD patients (35 males, 21 females, age 67 ± 14 years), with stages 4 and 5 renal failure, selected from a tertiary hospital renal outpatient clinic participated in this study. Subjects answered a questionnaire to assess upper GI symptoms and tested for the genetic taste recognition thresholds of thiourea, phenylthiocarbamide and sodium benzoate. Saliva samples were collected to determine biochemical composition. Possible associations between genetic taste variations, saliva composition and upper GI symptoms were investigated. RESULTS: Of the 56 patients enroled, 29 (52%) reported major upper GI uraemic symptoms, whereas 27 (48%) had no symptoms or only minor complaints of dry mouth. There was a strong association between the symptomatic burden a patient experienced and the genetic ability to taste thiourea (P o 0.0003). Uraemic symptoms of taste changes (P o0.004) and nausea (P o0.002) were found to be related to a patient's genetic ability to taste thiourea. CONCLUSIONS: This study provides evidence that the genetic ability to taste thiourea as bitter, in combination with the increase in active compounds found in CKD patient's saliva, impacts on the uraemic upper GI symptoms experienced.
INTRODUCTION
Fluid imbalance, toxin accumulation and metabolic derangements are a feature of chronic kidney disease (CKD). Uraemic symptoms including nausea, vomiting, dry retching, weight loss, dry mouth and taste abnormalities tend to worsen as renal function declines. 1, 2 Uraemic symptoms usually develop as creatinine clearance falls and plasma urea rises, although some patients remain non-symptomatic even when reaching stage 5 kidney disease with estimated glomerular filtration rate (eGFR) o10 ml/min. 3 CKD patients generally have significantly higher concentrations of urea, sodium, potassium, phosphate and pH levels in their saliva, with taste and smell functions also often impaired compared with those without CKD. [4] [5] [6] [7] [8] [9] Taste is defined as the chemical stimulation of taste receptor cells in the oral cavity, which perceive the primary tastes of sweet, sour, salty, bitter and umami. Humans have strong food-related biases with a general liking for sweet things and a dislike for bitter tastes, which enables the enjoyment of food while avoiding toxin ingestion. 10 Taste, especially the ability to taste bitter, is controlled by many genes of which some can be easily tested, such as thiourea, which has a nauseating or a bitter taste, and phenylthiocarbamide (PTC), which has a bitter taste to those who can taste them. The ability to taste either appears to be inherited. 11 Those who can taste thiourea will not necessarily taste PTC or the reverse. 12 Sodium benzoate is another known genetic test for taste, which can be perceived as salty, sour, bitter or sweet or not tasted at all. 10 The aim of this study was to investigate any associations between known taste genetics, saliva composition and upper gastrointestinal (GI) symptoms in CKD patients.
SUBJECTS AND METHODS
CKD patients with a recorded eGFR o 30 ml/min (stage 4 and 5 kidney disease) were recruited from the Austin Health renal outpatient clinic. Exclusion criteria included the inability to understand or sign the consent form or commenced dialysis. A convenience sample was used with a total of 56 CKD patients included in the study (n = 56, 35 males, 21 females, age 67 ± 14 years, eGFR o30 ml/min). The study was approved by the Austin Health Human Research Ethics Committee.
All participants were tested for genetically inherited taste recognition thresholds using taste testing strips (Carolina Genetics Burlington North Carolina), which were impregnated with either 30 mg thiourea, 30 mg PTC or 30 mg sodium benzoate. Edible taste strips used for measuring taste recognition thresholds are simple diagnostic tools used extensively in biology classrooms and research laboratories throughout the world. The taste strip for the bitter tasting compound thiourea has been validated 13 as non-tasters could not detect a taste at o 800 nmol. The taste response for PTC has been shown to be stable over a lifetime of an individual and is typically measured using the PTC strips and recording the subjects perception to determine an individual's level of PTC sensitivity and has been validated by Smutzer. 13 Participants were asked to trial each taste test strip in a random order by applying a strip to their moistened tongue and recording whether it had no taste or tasted bitter, salty, sour, sweet or any other taste. Patients were classified as non-tasters with no taste reported, tasters when a recognisable taste was identified and hyper-tasters if an intense bitter taste was experienced.
All patients were asked to complete a questionnaire that was then validated by interview regarding occurrence of any taste changes or upper GI symptoms. The series of questions assessed common CKD patient symptoms including experience of a dry mouth, taste changes, nausea, dry retching and vomiting. Each patient was required to indicate the duration of the symptom and its severity on a 1-10 visual analogue scale. Patients were then interviewed by the investigator of the project with patient descriptions of GI symptoms compared with current definitions. Symptom severity scores were compared before and after questionnaire versus interview. Of the 56 patients recruited, 45 patients described all symptoms correctly, whereas 11 patients incorrectly assigned dry retching as vomiting.
Saliva samples were collected to determine biochemical composition and salivary pH. A 1-ml saliva sample was collected from each participant by chewing on the cotton wool swab supplied with the saliva collection kit (Salivette, Sarstedt, Nümbrecht, Germany). At least 30 min after eating participants rinsed their mouth with water, the swab was placed inside the mouth and gently chewed for~1 min or until a sufficient quantity of saliva was produced. The swab was then withdrawn and placed into the polypropylene tube. Biochemical analysis of the saliva samples was performed by the Pathology Department at Austin Health on the same day of testing using a Roche Cobas c 501 Automated analyser system (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Samples were centrifuged at 4000 r.p.m. for 10 min after which the cotton wool was withdrawn. Sodium, potassium, bicarbonate, calcium, phosphate and urea were analysed using a number of techniques including indirect potentiometry, selective electrode enzymatic rate and colorimetric methods. Electrolyte concentrations were expressed as mmol/l. Blood samples were obtained close to outpatient appointment dates and analysed by the Austin Pathology Department using standard methodology.
The saliva sample collection, the genetic taste strips testing, the questionnaire completion, a 24-h dietary recall assessment and interview were all completed during the outpatient visit.
Statistical analysis
The participants' demographic, clinical and laboratory characteristics were compared using independent sample t-tests for continuous data and Fisher's exact tests for ordinal data. Frequencies of response for upper GI symptoms and response to genetic taste testing were estimated as a percentage per group. The strength of association between genetic taste testing and upper GI symptoms was estimated using the Spearman Rank correlation method. The value of P = 0.05 was considered as the threshold for statistical significance. All statistical analyses were conducted using SPSS statistical software Ver. 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The 56 recruited patients' baseline demographic, clinical and laboratory characteristics are shown in Table 1 . Biochemical parameters measured in saliva in the study population of patients reporting significant uraemic symptoms (n = 29) are compared with patients experiencing minimal uraemic symptoms (n = 27). In comparing the symptomatic group and the non-symptomatic groups, the parameters that reached statistical significance were eGFR (P o 0.009) with non-symptomatic patients actually recording worse renal function than that of symptomatic patients (P o 0.011). This may be due to the fact that symptomatic patients have a tendency to commence dialysis earlier. Overall, more renal patients were male, as typically men comprise~60% of the renal disease population worldwide. Women were found to be more symptomatic than men P o0.022 in this study, and it is recognised that women are more likely to be super-tasters compared with men. 14, 15 Salivary composition of all CKD study patients differed from normal with levels of potassium, bicarbonate and urea found to be significantly higher in CKD compared with non-renal patients as experienced in previous studies. [5] [6] [7] [8] [9] Symptomatic patients were generally more sensitive to the genetic taste strips and were significantly more likely to be hypertasters of thiourea P o0.0003 (Figure 1 ). The ability to taste PTC showed no significant association with upper GI symptoms, whereas there was a trend between the ability to taste sodium benzoate as sweet or salty with uraemic symptoms experienced, but this did not reach statistical significance.
Relationships between upper GI symptoms and the genetic taste test for thiourea in the study population are shown in Figure 2 . The genetic hyper taste recognition threshold of thiourea was related to total symptom burden reaching statistical significance for taste changes (P o0.004) and nausea (P o 0.002) with a relationship to dry retching at Po 0.06. The ability to taste sodium benzoate as sweet and complaints of taste changes demonstrated a trend but did not reach significance at P o0.09.
DISCUSSION
This is the first study to investigate any relationships between upper GI symptoms, saliva composition and the inherited genetic traits of taste in CKD patients. The correct diagnosis of uraemic symptoms is the first step in the development of treatments for these symptoms.
Humans can detect only five tastes using taste buds alone, sweet, bitter, sour, salt and umami, which are critical for nutrition and survival. Flavour is a broad phenomenon encompassing the senses of taste, smell and touch to enable the perception of sensations with far greater complexity than the five basic tastes alone. 16 Human saliva naturally contains chemicals that elicit the five basic tastes: sweet-glucose, salt-sodium, umami-glutamate, sour-acids and bitter-urea. The only food or fluid generally not tasted is one's own saliva because of taste familiarisation. 10 Supertasters have an increased number of taste buds on their tongue, which intensifies all tastes. 10 Women are born with more taste buds compared with men, and taste bud number only decreases after menopause; hence, females have been found to have greater sensitivity to all the tastes (35% of women versus 15% of men) 15 as was also found in the present study with 66% of the women compared with 44% of males complaining of upper GI uraemic symptoms. 
Taste genetics and GI sympotms in CKD
Taste is a trait controlled by many genes. Most of the genetic taste traits concern the bitter perception as it is particularly important in protecting against the ingestion of naturally toxic substances. Individual tolerance varies more widely for bitter than for any of the other basic tastes. Compounds such as amino acids, peptides, esters, organic and inorganic salts contribute to the bitter tastes in products such as coffee, tea, chocolate, saccharin, wine and some fruits and vegetables. 16 Bitter perception occurs through the bitter taste receptors encoded by the T2R genes, which identify between 25 different members of this gene family. 17 These differences may allow a wide variety of chemical shapes, sizes and functionalities to be bound by these receptors and be perceived as bitter. 18 Even among tasters these chemicals can only be detected if it is dissolved in the taster's own saliva, not in water or someone else's saliva. 16 Thiourea is an organosulphur compound SC(NH 2 ) 2 which is structurally similar to urea CO(NH 2 ) 2 , with the oxygen atom replaced by a sulphur atom, but their properties differ significantly. The ability to taste thiourea is dominantly inherited and is related to taste bud density and genetic expression of the taste receptor gene TAS2R38. 17 People are classified as non-tasters, tasters or hyper-tasters. About 70% of people can taste thiourea with~30% finding it incredibly nauseating or bitter, and tasters will tend to avoid any bitter foods like dark-green leafy vegetables, coffee or dark chocolate. 16 PTC, also known as phenylthiourea, is an organosulphur thiourea containing a phenyl ring. The ability to taste PTC mainly as bitter is also inherited and determined by a pair of alleles, with the allele for tasting being dominant over that for non-tasting. 18 Thiourea is closely related chemically to PTC, but the ability to taste either is inherited independently; hence, the taster and the non-taster groups for the two substances need not be the same. 18 Hyper tasters of PTC tend to be more sensitive to spicy and sweet foods and find fatty foods, broccoli and grapefruit juice less appealing. 17 Thiourea compounds are antithyroid agents, and non-tasters have been found to have higher rates of thyroid disease. 19 Sodium benzoate is often used as a preservative in foods. It can taste sweet, salty, bitter, sour, a combination of these or not tasted at all. The ability to taste sodium benzoate is also inherited independently of the sensitivity to PTC and thiourea but apparently can interact markedly on the effect of a person's reaction to various foods and tastes. 20 Taste dimorphism is also noticed with other substances such as barium sulphate emulsions and creatine. Creatine is tasteless to some people but bitter to others, and as lean meat contains creatine this taste idiosyncrasy may well account for the meat aversion experienced as creatine rises in renal failure. 21 Issues with taste and GI problems in renal failure are common, ranging from 31 to 81%. 8, [22] [23] [24] Alterations in perception have been identified for each of the five basic taste qualities in renal disease. 8, 22 Taste and smell disturbances may relate to issues presented with fluid imbalance, toxin accumulation and metabolic derangements characteristic of kidney disease. [23] [24] [25] This may be intensified by specific taste genetics sensitive to the increased saliva urea concentrations found in CKD.
Nausea typically accompanies toxin-induced illnesses. As most toxins taste bitter, nausea and dry retching often result even before the ingestion of the toxin. 26, 27 People who are most sensitive to the bitter stimuli are more prone to motion sickness 28 and nausea in pregnancy. 29 The bitter taste also slows down gastric emptying and is strongly sensed by the glossopharyngeal and vagus nerves, which innervate the posterior oral cavity and the GI tract, respectively, causing dry retching. 29 It has been shown that bitter taste stimulation, but not sweet, salty or umami taste, induces nausea. 30 This study suggests that CKD patients have a variety of upper GI symptoms, and differences in these symptoms were observed despite all patients having similar blood and saliva profile. The symptoms demonstrated greater association with the genetic ability to taste thiourea as bitter combined with the increased electrolytes and urea excreted in the saliva. As salivary fluid may involve taste-active compounds such as sodium, potassium, bicarbonate and urea, there is potential for these to directly influence taste perception and some uraemic GI symptoms. Changes in taste and the development of uraemic symptoms may be dependent on an individual's genetic taste profile with increased sensitivities to raised and changing saliva levels of a variety of tastant chemicals, the most important being urea.
Saliva is mainly water containing small amounts of various electrolytes including sodium, potassium, chloride, bicarbonate, calcium and phosphate as well as proteins, enzymes and nitrogenous products such as urea and ammonia. Saliva flows from acini to the collecting ducts where the composition of saliva is managed with sodium being actively reabsorbed, whereas potassium and phosphate are secreted. 31 Saliva electrolyte composition resembles urine levels rather than blood plasma, and concentrations of salivary urea have been validated as a method to diagnose CKD. 32 Many studies have demonstrated that CKD patients have altered salivary composition compared with those without the disease. 8, 11, 12 The CKD patients in this study also demonstrated increased salivary potassium, bicarbonate, phosphate and urea compared with healthy individuals.
Excretory high salivary concentration of taste-active compounds (for example, sodium and urea) can directly influence taste perception by reducing taste sensitivity. 32 Presence of sodium ions affects salt taste; urea is thought to affect bitter and sweet perception, whereas bicarbonate increases buffering capacity, neutralising hydrogen ions, thereby affecting sour and umami taste perception. 24 Despite symptomatic patients complaining of anorexia and taste changes, most had normal or high body mass indexes and only a small number lost weight. This phenomenon has been also observed where no association between taste function and body mass index has been found. 33 Taste alterations can lead to obesity or malnutrition as differences in genetics of taste are known to influence food preferences especially for vegetables. 20 The present findings demonstrated that CKD patients sensitive to thiourea have a higher level of upper GI symptoms of taste changes, nausea and dry retching. If therapies targeting saliva abnormalities can be implemented, patient comfort could be improved and the need for dialysis may be delayed without comprising nutritional status. 38 Some limitations should be mentioned when considering results from this study. Not all 25 genetic taste sensitivities to bitter are known or can be easily be tested. Genetic taste interactions are also not fully understood, therefore not allowing for complete analysis. An increased number of subjects may also have allowed for interactions between taste genetics to be assessed.
CONCLUSION
This study provides evidence that the genetic ability to taste thiourea impacts on taste perception and nausea in CKD patients with the raised levels of urea found in their saliva. Further research is required to clearly establish whether changing the saliva environment is possible, thereby improving uraemic symptoms and taste sensitivity in CKD patients.
These observations expand on our understanding of this complex research area, adding to the existing body of literature and providing new evidence regarding the mechanisms behind some uraemic GI manifestations experienced in CKD patients.
Practical application
The correct diagnosis of taste changes and upper GI symptoms is necessary to explore possible treatment options. This study may have important implications for clinical practise not only for patients with kidney disease but also for those with taste changes, nausea or dry retching in other conditions such as chemotherapy and pregnancy. CKD patients who have the genetic ability to taste thiourea at low thresholds were shown to experience high levels of upper GI symptoms, which appears to be related to changed levels of saliva electrolytes, especially urea. Uraemic symptoms may be modifiable by a change in renal patient's saliva composition and the techniques to override the sensitivity to bitter need to be explored. Food industries have developed bitter blockers, food tasters have techniques to cleanse the palate and mouth washes are regularly used in those with oral issues.
The ability to minimise uraemic symptoms will maximise patient comfort for those not for renal replacement and delay the need for dialysis, thereby decreasing the financial burden on health systems.
